Table of Contents
TNBC와 basal-like는 겹쳐진다.
Epidemiology and risk factors for TNBC #
Higher rates in
- Younger women
- BRCA1 expression
- African, Hispanic ancestry
- Luminal A --> late born metastasis
- TNBC --> early visceral metastasis
Limitations of current treatment strategies for TNBC #
Current treatment strategy
chemotherapy TNBC는 luminal A, B 보다 높은 progression-free survival 반응율을 가진다. 그러나 짧은 disease-free survival, overal survival.
Platinum salts in TNBC #
It's for all breast cancers.
Other potential treatment targets in TNBC #
Androgen receptor treated target #
Expression 데이터로 clustering 했을 때, ER- 쪽에 속하는 ER+ 몇개가 있음. --> ER은 없지만, downstream 발현이 ER+와 유사, 그리고, AR 높음.
AR is widely expressed in breast cancer.
Addressing current unmet needs in clinical practice #
61개 이상의 TNBC 임상연구가 ClinicalTrails.gov에 보고됨
Incoming Links #
Related Articles (Article 0) #
Suggested Pages #
- 0.150 BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells
- 0.050 Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
- 0.025 Vascular endothelial growth factor
- 0.025 VPF
- 0.025 BRCA2
- 0.025 Cell-free tumor DNA
- 0.025 Vasculogenesis
- 0.025 Paclitaxel
- 0.025 Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer
- More suggestions...